A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)

  • Fedele, Pasquale (Primary Chief Investigator (PCI))
  • Gregory, Gareth (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date9/08/21 → 8/08/26

Keywords

  • phase 3 study
  • treatment safety
  • treatment efficacy
  • lymphoma